EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023

Jennifer DeCuir, Diya Surie iD, Yuwei Zhu, Adam S Lauring, Manjusha Gaglani, Tresa McNeal, Shekhar Ghamande, Ithan D Peltan, Samuel M Brown, Adit A Ginde, Aimee Steinwand, Nicholas M Mohr iD und 41 weitere

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.70027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Jennifer DeCuir und 52 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: COVID-19, Hospitalization, COVID-19 Vaccines, Vaccine Efficacy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, CDC HHS, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Assessments of COVID‐19 vaccine effectiveness are needed to monitor the protection provided by updated vaccines against severe COVID‐19. We evaluated the effectiveness of original monovalent and bivalent (ancestral strain and Omicron BA.4/5) COVID‐19 vaccination against COVID‐19‐associated hospitalization and severe in‐hospital outcomes.

Methods

During September 8, 2022 to August 31, 2023, adults aged ≥ 18 years hospitalized with COVID‐19‐like illness were enrolled at 26 hospitals in 20 US states. Using a test‐negative case–control design, we estimated vaccine effectiveness (VE) with multivariable logistic regression adjusted for age, sex, race/ethnicity, admission date, and geographic region.

Results

Among 7028 patients, 2924 (41.6%) were COVID‐19 case patients, and 4104 (58.4%) were control patients. Compared to unvaccinated patients, absolute VE against COVID‐19‐associated hospitalization was 6% (−7%–17%) for original monovalent doses only (median time since last dose [IQR] = 421 days [304–571]), 52% (39%–61%) for a bivalent dose received 7–89 days earlier, and 13% (−10%–31%) for a bivalent dose received 90–179 days earlier. Absolute VE against COVID‐19‐associated invasive mechanical ventilation or death was 51% (34%–63%) for original monovalent doses only, 61% (35%–77%) for a bivalent dose received 7–89 days earlier, and 50% (11%–71%) for a bivalent dose received 90–179 days earlier.

Conclusion

Bivalent vaccination provided protection against COVID‐19‐associated hospitalization and severe in‐hospital outcomes within 3 months of receipt, followed by a decline in protection to a level similar to that remaining from previous original monovalent vaccination by 3–6 months. These results underscore the benefit of remaining up to date with recommended COVID‐19 vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HospitalizationCOVID-19 VaccinesVaccine EfficacySARS-CoV-2HumansMaleFemaleUnited StatesMiddle AgedAgedAdultCase-Control StudiesYoung AdultVaccinationAged, 80 and overAdolescent

Stichwörter der Autor:innen

COVID‐19COVID‐19 vaccinesUnited Statesadulthospitalization

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Departments of Internal Medicine and Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
  • Baylor College of Medicine, Baylor Scott & White Health, Temple and Dallas, Texas, Temple, Texas, USA.
  • Baylor College of Medicine, Baylor, Scott & White Health, Temple, Texas, USA.
  • Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, Murray, Utah and University of Utah, Salt Lake City, Utah, USA.

ORCID-Profile: Diya Surie, Nicholas M Mohr, Akram Khan, Ivana A Vaughn, Nathaniel Lewis, Meredith McMorrow

Förderung

  • NIGMS NIH HHS
  • CDC HHS
  • Centers for Disease Control and Prevention

Zitieren

APA

DeCuir, J., Surie, D., Zhu, Y., Lauring, A. S., Gaglani, M., McNeal, T., Ghamande, S., Peltan, I. D., Brown, S. M., Ginde, A. A., Steinwand, A., Mohr, N. M., Gibbs, K. W., Hager, D. N., Ali, H., Frosch, A., Gong, M. N., Mohamed, A., Johnson, N. J., …, & Investigating Respiratory Viruses in the Acutely Ill (IVY) Network (2024). Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70027

Vancouver

DeCuir J, Surie D, Zhu Y, Lauring AS, Gaglani M, McNeal T, et al. Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.70027

BibTeX
@article{DeCuir2024,
  author = {DeCuir, Jennifer and Surie, Diya and Zhu, Yuwei and Lauring, Adam S and Gaglani, Manjusha and McNeal, Tresa and Ghamande, Shekhar and Peltan, Ithan D and Brown, Samuel M and Ginde, Adit A and Steinwand, Aimee and Mohr, Nicholas M and Gibbs, Kevin W and Hager, David N and Ali, Harith and Frosch, Anne and Gong, Michelle N and Mohamed, Amira and Johnson, Nicholas J and Srinivasan, Vasisht and Steingrub, Jay S and Khan, Akram and Busse, Laurence W and Duggal, Abhijit and Wilson, Jennifer G and Qadir, Nida and Chang, Steven Y and Mallow, Christopher and Kwon, Jennie H and Exline, Matthew C and Shapiro, Nathan I and Columbus, Cristie and Vaughn, Ivana A and Ramesh, Mayur and Safdar, Basmah and Mosier, Jarrod M and Casey, Jonathan D and Talbot, H Keipp and Rice, Todd W and Halasa, Natasha and Chappell, James D and Grijalva, Carlos G and Baughman, Adrienne and Womack, Kelsey N and Rhoads, Jillian P and Swan, Sydney A and Johnson, Cassandra and Lewis, Nathaniel and Ellington, Sascha and Dawood, Fatimah S and McMorrow, Meredith and Self, Wesley H and Investigating Respiratory Viruses in the Acutely Ill (IVY) Network, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network},
  title = {Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.70027}
}
Kostenlos starten →